
Xanax, also known as alprazolam, is not a recognized cause of peripheral neuropathy. Its prescribing information, the label approved by the United States Food and Drug Administration (FDA), gives two indications, the acute treatment of generalized anxiety disorder and the treatment of panic disorder, and the word neuropathy appears nowhere in it.
Yet, people who type “Xanax neuropathy” into a search engine are not imagining things. They have tingling in the hands or feet, patches of numbness, burning in the soles, or a jolt like a small electric shock, and they want to know whether the medication did it.
The sensations are real, they usually are caused by the medication, and they usually are not nerve damage. They are withdrawal symptoms, and that difference decides what should happen next.
Peripheral neuropathy means injury to the nerves outside the brain and spinal cord. Diabetes, vitamin B12 deficiency, thyroid disease, and certain toxins are the usual causes, and the symptoms tend to be steady, symmetrical, and slowly progressive, often beginning in the feet.
Benzodiazepine withdrawal can sound identical when a patient describes it. Professor C. Heather Ashton, in Chapter III of the Ashton Manual (benzo.org.uk) under the heading “Bodily sensations,” writes that strange tingling, pins and needles, patches of numbness, feelings of electric shock, hot and cold sensations, itching, and deep burning pain are not uncommon in benzodiazepine withdrawal.
During withdrawal, she explains, the sensory nerves and their connections in the spinal cord and brain become hyperexcitable. The nerve is not injured. It is overreacting.
Imagine a smoke detector with its sensitivity turned all the way up. Burnt toast sets it off, shower steam sets it off, and the alarm is loud and real, but there is no fire. While this is not a perfect analogy, a withdrawing sensory nerve behaves the same way: the tingling and burning are the alarm, not the fire.
Withdrawal does not wait for the last pill. Alprazolam boosts the effect of gamma-aminobutyric acid (GABA), the brain’s main calming signal, and over months of daily use the nervous system adapts by turning its own calming machinery down, so the same dose covers less than it used to. Patients call this tolerance withdrawal, and in Chapter I of the Manual Professor Ashton describes anxiety symptoms that gradually increase over the years despite continuous benzodiazepine use.
The second situation is the gap between doses. Alprazolam is short acting, with a half-life of six to twelve hours in the Manual’s Table 1, and the Xanax label itself reports early morning anxiety and anxiety symptoms between doses in patients with panic disorder on prescribed maintenance doses, which it attributes to tolerance or to a dose interval longer than the drug’s action. The same clock governs every withdrawal symptom, tingling included, so pins and needles at four in the morning, or an hour before the next tablet is due, point to timing, not nerve disease.
The third situation is a reduction that outruns the nervous system. Cutting the dose too fast, or stopping cold turkey, brings the same sensory storm along with the dangerous withdrawal reactions, the most serious of which is a seizure. A seizure is a medical emergency: call 911 or your local emergency services at once.
After the FDA’s 2020 boxed-warning update for the whole benzodiazepine class, the Xanax label gained a section on dependence and withdrawal reactions. Its description of protracted withdrawal syndrome names anxiety, cognitive impairment, depression, insomnia, formication, a crawling feeling on the skin, motor symptoms such as weakness, tremor, and muscle twitches, paresthesia, and tinnitus, persisting beyond four to six weeks and, in some patients, lasting more than twelve months.
Paresthesia is the medical word for tingling, prickling, and numbness. In other words, the manufacturer’s own document places the sensation you are searching about under withdrawal, not under nerve injury.
A person who took Xanax exactly as prescribed for months or years and now has tingling between doses has done nothing wrong. The nervous system adapted to the drug, which is physical dependence, and dependence is not addiction.
Addiction is defined by behavior, meaning compulsive use that continues despite harm. Dependence is defined by physiology, meaning the body has adjusted and protests when the drug level falls. Nearly every patient who comes to Dr. Leeds for tapering has the second and not the first.
The distinction matters because the wrong label leads to the wrong treatment. Programs built for addiction run short, fixed schedules that make withdrawal sensations worse, and they treat the person as a problem to correct rather than a patient with a medical condition. Unfortunately, a patient who mentions numbness and burning in the wrong office can leave with that label.
Withdrawal is the most common explanation, but it is not the only one, and a careful physician checks. Diabetes and prediabetes, vitamin B12 deficiency, and thyroid disease are ordinary causes of neuropathy that a blood test can find. Two things can be true at once: withdrawal paresthesias and a low B12 level in the same patient.
Some patterns point away from withdrawal. Symptoms that stay on one side, follow a single nerve, come with true weakness or a lost reflex, or progress steadily instead of coming and going deserve a neurological examination. Professor Ashton notes in Chapter III that withdrawal symptoms characteristically wax and wane from day to day and even within a day, a strong clue that the nerves are irritated rather than injured.
So, the order is simple. Check the ordinary causes, look at the pattern and the timing, and then treat the withdrawal as withdrawal.
The answer is not a second prescription for nerve pain. Dr. Leeds tapers psychiatric medications, and he does not add them to treat the symptoms of tapering, because the tingling is a message about the taper, which is what he adjusts.
First, he looks at timing. When the sensations cluster before doses, the problem is usually the short action of alprazolam, and the Ashton Manual’s answer, in Chapter II, is a crossover taper to diazepam, a long-acting benzodiazepine that keeps blood levels steady between doses. Table 1 of the Manual rates alprazolam 0.5 mg as roughly equal to diazepam 10 mg, with Professor Ashton’s caution that equivalents vary from person to person, so the figure shows how a crossover is sized and is not a schedule to run alone.
When the sensations appear after a cut, he slows the taper or holds the dose until they settle. The Xanax label says the same thing in its own language: if withdrawal reactions develop, consider pausing the taper or returning to the previous dose, then reduce more slowly, and some patients need an even more gradual discontinuation.
The shape of the cuts matters too. Following the Maudsley Deprescribing Guidelines, Dr. Leeds uses hyperbolic reductions, meaning each step removes a smaller amount than the one before, so the last part of the taper comes off in the smallest slivers, often as a compounded liquid. The whole process takes months, sometimes longer, and it is patient directed: if the rate is too fast, Dr. Leeds must advise slowing down, and if a patient feels ready to go a bit faster, patient and doctor may agree to try, as tolerated.
This is what his medically supervised benzodiazepine tapering looks like in practice, with the Ashton Manual approach as its backbone. Getting back to the smoke detector, the fix is not to tear it off the ceiling. It is to turn the sensitivity down a little at a time, which is what a slow taper does.
Is withdrawal tingling permanent? In most cases it is not, but after months of pins and needles that come and go, it can feel as if it is. The label acknowledges protracted symptoms lasting more than twelve months in some patients, and the Manual’s verdict on the same sensations is that, though disconcerting, they are usually nothing to worry about.
Both are true, and nobody can promise a date. Fortunately, the same nervous system that learned to lean on the drug can learn to stand without it when given time, and a slower taper produces fewer of these sensations.
Tell your doctor when the tingling comes, not just that it comes. The timing is information, and it changes the plan.
Informed consent comes first: the risks of continuing and of tapering, the alternatives, an exit plan from the start, and the right to decline or pause at any point. The pace belongs to the patient.
Dr. Leeds’ practice in Fort Lauderdale offers one thing to patients in Florida: medically supervised benzodiazepine and z-drug tapering, with one physician who works directly with every patient. Patients who arrive asking whether Xanax caused their neuropathy usually leave with a different question: how slowly should the taper go? Contact Dr. Leeds to talk through a taper plan built around your own nervous system.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.

Mark Leeds, D.O. is an osteopathic physician and deprescribing specialist in Fort Lauderdale, Florida. He helps patients come off benzodiazepines and sleeping pills with a slow, patient-directed taper guided by the Ashton Manual and the Maudsley Deprescribing Guidelines. Physical dependence is not addiction, and a careful taper is measured in months, not days.
Contact Us for expert guidance on safely tapering off benzodiazepines and reclaiming your life.





